Featured Research

from universities, journals, and other organizations

Cold Virus With P53 Gene Tested To Combat Ovarian Cancer

Date:
October 30, 1998
Source:
University Of Texas Southwestern Medical Center At Dallas
Summary:
Researchers at UT Southwestern Medical Center at Dallas are using the p53 gene, inserted into an inactive common-cold virus, as a novel way to attack ovarian cancer in a patient.

DALLAS - October 28, 1998 - Researchers at UT Southwestern Medical Center at Dallas are using the p53 gene, inserted into an inactive common-cold virus, as a novel way to attack ovarian cancer in a patient.

Drs. Carolyn Muller and Robert Coleman, assistant professors of obstetrics and gynecology, said p53 is known as the housekeeper gene because it patrols for damaged cells, and if the cells cannot be repaired or are growing out of control and can't be contained, the p53 gene turns on its second line of defense: a built-in cell-death program, a process called apoptosis. The p53 mutations are the most common mutations in solid tumors and are found in 50 percent to 79 percent of ovarian cancers.

Muller said the normal p53 genes are replicated in the laboratory and inserted into adenoviruses, which act as carriers. During the treatment procedure, the patient's large amount of abdominal fluids, caused by the cancer, is withdrawn, and a therapeutic mixture of engineered p53 genes floating in saline is injected into the abdominal cavity. There the viral "geneboats" deliver the p53 gene to all cells. Once the gene is turned on in cancer cells, the invading "housekeeper" goes to work, recognizes the cancer cell's DNA damage and condemns it to death.

Muller and Coleman, who work in the Harold C. Simmons Comprehensive Cancer Center and the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research, said that this trial will determine several things. They include the appropriate mixture of engineered viruses in the solution, the sequence of doses, the length of treatment and the manner in which the patient reacts to it. The first patient's treatments are occurring in three weekly visits with two-week intervals between them. Patients will continue treatments as long as a positive response occurs unless significant side effects develop. Fifteen to 18 patients are expected to be treated in this study.

Nancy Ruff, a 65-year-old wife, mother and grandmother, never intended to be a pioneer. But when she was referred to Coleman and Muller to discuss the first human p53 trial for ovarian cancer, she had run out of treatment options. Ruff had gone through two surgeries and six different chemotherapies in the last two years. She said that after each chemotherapy series she felt better for a while, but signs of the cancer would reappear.

Ruff's ovarian cancer was discovered when she had an endoscopy for an ulcer that wouldn't heal. Later she learned that she also suffered from a hernia, so she hadn't connected the "bloaty feeling," often symptomatic of ovarian cancer, with any other illness.

"The first time I went to see the Southwestern doctors, I took six pages of typewritten questions in with me, so I wouldn't forget anything I wanted to ask," Ruff said.

Ruff said that "so far the treatment at its worst is like a bad case of the flu. And I know what I'm talking about since I've had a lot of chemotherapy." She's also delighted that the p53 treatment doesn't cause her to lose her hair.

The two researchers have been part of a large medical team that has been looking at using the p53 gene for four years - performing extensive studies with genetically engineered cells and animals - before receiving approval from the National Cancer Institute to treat women with "advanced, persistent or recurrent ovarian cancer."

The researchers hope that therapy with the engineered p53 gene may provide a strong second front for fighting ovarian cancer because of the low survival rates with surgery and chemotherapy. "With this trial, we will learn a lot about the how the gene works in humans, and we will be able to improve the treatment strategy for future patients," Muller said.

For further information, stage III and IV ovarian cancer patients or their physicians should call clinical research nurse Paula Rogers at (214) 648-2806.


Story Source:

The above story is based on materials provided by University Of Texas Southwestern Medical Center At Dallas. Note: Materials may be edited for content and length.


Cite This Page:

University Of Texas Southwestern Medical Center At Dallas. "Cold Virus With P53 Gene Tested To Combat Ovarian Cancer." ScienceDaily. ScienceDaily, 30 October 1998. <www.sciencedaily.com/releases/1998/10/981030082144.htm>.
University Of Texas Southwestern Medical Center At Dallas. (1998, October 30). Cold Virus With P53 Gene Tested To Combat Ovarian Cancer. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/1998/10/981030082144.htm
University Of Texas Southwestern Medical Center At Dallas. "Cold Virus With P53 Gene Tested To Combat Ovarian Cancer." ScienceDaily. www.sciencedaily.com/releases/1998/10/981030082144.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins